Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 1/2014

01-02-2014 | Brief Report

Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005–2012

Authors: A. Greenbaum, S. S. Chaves, A. Perez, D. Aragon, A. Bandyopadhyay, N. Bennett, B. Fowler, E. Hancock, R. Lynfield, C. McDonald-Hamm, A. Reingold, P. Ryan, W. Schaffner, R. Sharangpani, M. Spencer, A. Thomas, K. Yousey-Hindes, S. Zansky, L. Finelli

Published in: Infection | Issue 1/2014

Login to get access

Abstract

We examined heavy alcohol use as a risk factor for severe influenza (intensive care admission or death) among hospitalized adults. In <65- and ≥65-year-olds, heavy alcohol use increased disease severity [relative risk (RR) 1.34; 95 % confidence interval (CI): 1.04–1.74, and RR 2.47; 95 % CI: 1.69–3.60, respectively]. Influenza vaccination and early, empiric antiviral treatment should be emphasized in this population.
Footnotes
1
Persons at higher risk for influenza complications include persons aged ≥65 years; persons with chronic pulmonary (including asthma), cardiovascular (except hypertension alone), renal, hepatic, hematological (including sickle-cell disease), metabolic disorders (including diabetes mellitus), or neurological and neurodevelopment conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle, such as cerebral palsy, epilepsy, stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury); and persons with immunosuppression, including that caused by medications or HIV infection. For a complete list, see “Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010” [5].
 
Literature
1.
2.
Saitz R, Ghali WA, Moskowitz MA. The impact of alcohol-related diagnoses on pneumonia outcomes. Arch Intern Med. 1997;157:1446–52.PubMedCrossRef
3.
Zhang P, Bagby GJ, Happel KI, Summer WR, Nelson S. Pulmonary host defenses and alcohol. Front Biosci. 2002;7:d1314–30.PubMedCrossRef
4.
5.
Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1–62.PubMed
6.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision, 2000.
7.
Meyerholz DK, Edsen-Moore M, McGill J, Coleman RA, Cook RT, Legge KL. Chronic alcohol consumption increases the severity of murine influenza virus infections. J Immunol. 2008;181:641–8.PubMedCentralPubMed
8.
Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 2011;8:e1001053.PubMedCentralPubMedCrossRef
9.
McKenna JJ, Bramley AM, Skarbinski J, Fry AM, Finelli L, Jain S; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Asthma in patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection—United States, 2009. BMC Infect Dis. 2013;13:57.PubMedCrossRef
10.
Merrick EL, Hodgkin D, Garnick DW, et al. Unhealthy drinking patterns and receipt of preventive medical services by older adults. J Gen Intern Med. 2008;23:1741–8.PubMedCentralPubMedCrossRef
Metadata
Title
Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005–2012
Authors
A. Greenbaum
S. S. Chaves
A. Perez
D. Aragon
A. Bandyopadhyay
N. Bennett
B. Fowler
E. Hancock
R. Lynfield
C. McDonald-Hamm
A. Reingold
P. Ryan
W. Schaffner
R. Sharangpani
M. Spencer
A. Thomas
K. Yousey-Hindes
S. Zansky
L. Finelli
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0534-8

Other articles of this Issue 1/2014

Infection 1/2014 Go to the issue

Case Report

Brucella canis peritonitis

Clinical and Epidemiological Study

SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients

Clinical and Epidemiological Study

How many outbreaks of nosocomial infections occur in German neonatal intensive care units annually?

Case Report

Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature

Clinical and Epidemiological Study

Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

Review

Turicella otitidis and Corynebacterium auris: 20 years on
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits